Ultragenyx Pharmaceutical (RARE) Q4 2025 earnings summary

Executive summary

• Achieved 20% year-over-year revenue growth in 2025, reaching $673 million, exceeding guidance, with commercial products contributing from over 35 countries and strong growth in Crysvita and Evkeeza sales.

• Strategic restructuring implemented, including a 10% workforce reduction (~130 employees), to align resources, reduce expenses, and target profitability by 2027.

• Two potential product approvals (MPS IIIA and GSDIa) and pivotal Angelman syndrome data expected in 2026, making it a pivotal year.

Financial highlights

• 2025 total revenue reached $673 million, up 20% from 2024 and above guidance, with Q4 revenue at $207 million (+25% YoY).

• Crysvita revenue was $481 million (+17% YoY), Dojolvi $96 million (+9% YoY), Evkeeza $59 million (+84% YoY), and Mepsevii $37 million.

• Net loss for 2025 was $575 million, or $5.83 per share.

• Year-end cash, cash equivalents, and marketable securities totaled $738 million.

• Operating expenses for 2025 were $1.2 billion, including $153 million in non-cash stock-based compensation.

Outlook and guidance

• 2026 revenue guidance: $730–$760 million (8–13% YoY growth), excluding new launches.

• Crysvita expected at $500–$520 million, Dojolvi at $100–$110 million.

• Combined R&D and SG&A expenses in 2026 projected to be flat or down slightly versus 2025; 2027 combined expenses expected to decrease at least 15% from 2025.

• Path to profitability in 2027 relies on continued double-digit growth from existing products, new launches, and cost reductions.